Agonist of V2 vasopressin receptor reduces depressive disorders in post-stroke patients

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 4, 2012, Pages 40-44

  Belokoskova, S G ^a   Stepanov, I I ^a   Tsikunov, S G ^a  

^a Institute of Experimental Medicine NWB RAMS   (Russian Federation)

Author keywords

Depression; Stroke; Vasopressin

Indexed keywords

ARGIPRESSIN[1 DEAMINO]; VASOPRESSIN RECEPTOR;

AGED; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG POTENTIATION; FEMALE; HUMAN; INSOMNIA; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PILOT STUDY; PSYCHOLOGICAL ASPECT; SLEEP; STROKE;

ADMINISTRATION, INTRANASAL; AGED; DEAMINO ARGININE VASOPRESSIN; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, VASOPRESSIN; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; STROKE;

EID: 84868328220     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: 10.15690/vramn.v67i4.197     Document Type: Article

References (14)

1. Tsikunov S.G., Belokoskova S.G. Psychophysiological analisis of the influence of vasopressin on speech in patients with post-stroke aphasias. Spanish J. Psychology. 2007; 1 (1): 180-190.
2. Tribollet E., Raufaste D., Maffrand J., Serradeil-Le Gal C. Binding of the non-peptide vasopressin Via receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study. Neuroendocrinology. 1999; 69 (2): 113-120. (Pubitemid 29082216)
3. Vaccari C., Lolait S.J., Ostrowski N.L. Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology. 1998; 139 (12): 5015-5033. (Pubitemid 28533450)
4. Kato Y., Igarashi N., Hirasawa A. et al. Distribution and developmental changes in vasopressin V2 receptor mRNA in rat brain. Differentiation. 1995; 59 (3): 163-169.
5. Liebsch G., Vfotjak C.T., Landgraf R., Engelmann M. Septal vasopressin modulates anxiety-related behaviour in rats. Neurosci. Lett. 1996; 217 (2-3): 101-104. (Pubitemid 26358812)
6. Griebel G., Simiand J., Serradeil-Le Gal C. et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. USA. 2002; 99 (9): 6370-6375. (Pubitemid 34493318)
7. Inder W.J., Donald R.A., Prickett T.C. et al. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol. Psychiatry. 1997; 42 (8): 744-747. (Pubitemid 27444511)
8. Aguilera G., Subburaju S., Young S., Chen J. The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Prog. Brain Res. 2008; 170: 29-39. 9.
9. rd ed. New- York: Psychology Press. 2008.
10. Conover W. J. Practical nonparametric statistics. New-York: Wiley. 1980.
11. Bortz J., Lienert G., Boehnke K. Verteilungsfreie Methoden in der Biostatistik. Berlin: Springer. 2000.
12. Di Michele S., Ericson M., Sillen U. et al. The role of catecholamines in desmopressin induced locomotor stimulation. J. Neural. Transm. 1998; 105(10-12): 1103-1115. (Pubitemid 29017393)
13. Zhou A.W., Li W.X., Guo J., Du Y.C. Facilitation of AVP(4-8) on gene expression of BDNF and NGF in rat brain. Peptides. 1997; 18(8): 1179-1187. (Pubitemid 28026887)
14. Chen Q., Patel R., Sales A. et al. Vasopressin-induced neurotrophism in cultured neurons of the cerebral cortex: dependency on calcium signaling and protein kinase C activity. Neuroscience. 2000; 101:19-26.